The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola.
A vaccine against Ebola: Problems and opportunities / Rezza, G. - In: HUMAN VACCINES & IMMUNOTHERAPEUTICS. - ISSN 2164-5515. - 11:5(2015), pp. 1258-1260. [10.1080/21645515.2015.1021528]
A vaccine against Ebola: Problems and opportunities
Rezza G
2015-01-01
Abstract
The unprecedented dimensions of the 2014 Ebola epidemic which ravaged 3West African countries have challenged public health response capacity and urged the availability of safe and effective vaccines. In this context, vectored vaccines already tested in animal models have undergone phase 1studies in human beings and are now ready for efficacy evaluation in large scale trials. Health care workers and other frontline caregivers are likely to be the target population for both vaccine trials and vaccination campaigns. However, methodological and ethical issues should be considered in plans concerning the conduction of clinical trials and the possible use of licensed vaccines against Ebola.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
